Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Incidence and risk factors for herpes zoster in patients with rheumatoid arthritis receiving upadacitinib: a pooled analysis of six phase III clinical trials
Kevin Winthrop, Peter Nash, Kunihiro Yamaoka, et al.
Annals of the Rheumatic Diseases (2021) Vol. 81, Iss. 2, pp. 206-213
Open Access | Times Cited: 55

Showing 26-50 of 55 citing articles:

Exploring the Link between Varicella-Zoster Virus, Autoimmune Diseases, and the Role of Recombinant Zoster Vaccine
Ryuhei Ishihara, Ryu Watanabe, Mayu Shiomi, et al.
Biomolecules (2024) Vol. 14, Iss. 7, pp. 739-739
Open Access | Times Cited: 3
Preventing herpes zoster in immunocompromised patients: Current concepts
Cassandra Calabrese, E. Kirchner, James Fernandez, et al.
Cleveland Clinic Journal of Medicine (2024) Vol. 91, Iss. 7, pp. 437-445
Open Access | Times Cited: 3
Integrated safety analysis of filgotinib for ulcerative colitis: Results from SELECTION and SELECTIONLTE
Stefan Schreiber, Gerhard Rogler, Mamoru Watanabe, et al.
Alimentary Pharmacology & Therapeutics (2023) Vol. 58, Iss. 9, pp. 874-887
Open Access | Times Cited: 8
Opportunistic infections associated with Janus kinase inhibitor treatment for rheumatoid arthritis: A structured literature review
Kevin Winthrop, John D. Isaacs, Leonard H. Calabrese, et al.
Seminars in Arthritis and Rheumatism (2022) Vol. 58, pp. 152120-152120
Open Access | Times Cited: 12
Protein kinase inhibitors as therapeutics in neurodegenerative and psychiatric disorders
Giuseppe Tridente, Ankit Jana, Arnab Nath, et al.
Elsevier eBooks (2023), pp. 403-573
Closed Access | Times Cited: 7
Systematic review and network meta-analysis of the risk of Herpes zoster with biological therapies and selective Janus kinase-1 inhibitors in atopic dermatitis
Daud Manzar, Nikhil Nair, Emmanuel Suntres, et al.
Advances in Dermatology and Allergology (2024) Vol. 41, Iss. 1, pp. 72-77
Open Access | Times Cited: 2
Prevalence and risk factors of herpes zoster infection in patients with rheumatic diseases not receiving biologic or targeted therapies
Chi Chiu Mok, Ling Yin Ho, Sau Mei Tse, et al.
Clinical Rheumatology (2022) Vol. 42, Iss. 4, pp. 1019-1026
Closed Access | Times Cited: 10
Clinical and Economic Burden of Herpes Zoster in Patients with Rheumatoid Arthritis: A Retrospective Cohort Study Using Administrative Claims
David Singer, Philippe Thompson‐Leduc, Sara Poston, et al.
Rheumatology and Therapy (2023) Vol. 10, Iss. 4, pp. 933-950
Open Access | Times Cited: 5
Safety of JAK inhibitor use in patients with rheumatoid arthritis who developed herpes zoster after receiving JAK inhibitors
Won‐Ho Choi, Soo Min Ahn, Yong‐Gil Kim, et al.
Clinical Rheumatology (2022) Vol. 41, Iss. 6, pp. 1659-1663
Closed Access | Times Cited: 9
Randomized, double-blinded, placebo-controlled phase I study of the pharmacokinetics, pharmacodynamics, and safety of KL130008, a novel oral JAK inhibitor, in healthy subjects
Na Li, Shuangqing Du, Ying Wang, et al.
European Journal of Pharmaceutical Sciences (2022) Vol. 176, pp. 106257-106257
Open Access | Times Cited: 8
Exploring the role of Janus kinase (JAK) in atopic dermatitis: a review of molecular mechanisms and therapeutic strategies
Toshiaki Kogame, Gyohei Egawa, Kenji Kabashima
Immunological Medicine (2023) Vol. 46, Iss. 3, pp. 112-120
Open Access | Times Cited: 4
Klinik und Therapie des Herpes zoster und der postherpetischen Neuralgie
Svea Hüning, M. Werner, L. Susok
Deleted Journal (2024) Vol. 75, Iss. 9, pp. 733-742
Closed Access | Times Cited: 1
Two cases of atypical herpes zoster in people taking oral Janus kinase inhibitors
Rebecca Green, Elaine Dupuis, Justin Chia
Canadian Medical Association Journal (2024) Vol. 196, Iss. 25, pp. E875-E877
Open Access | Times Cited: 1
Cumulative incidence and risk of infection in patients with rheumatoid arthritis treated with janus kinase inhibitors: A systematic review and meta-analysis
Konstantinos Ouranos, Diana Avila, Evangelia K. Mylona, et al.
PLoS ONE (2024) Vol. 19, Iss. 7, pp. e0306548-e0306548
Open Access | Times Cited: 1
The relationship between Zoster serology, vaccination uptake and infection rates: a single centre cross sectional study
Saad Ahmed, Martin Lauran, Adaeze Ugwoke, et al.
Rheumatology Advances in Practice (2024) Vol. 8, Iss. 4
Open Access | Times Cited: 1
Recent advance in management of herpes simplex in Japan
Shinichi Imafuku
The Journal of Dermatology (2023) Vol. 50, Iss. 3, pp. 299-304
Open Access | Times Cited: 2
Ocular side effects of oncological therapies: Review
M. Asencio Durán, Eva Fernández-Gutiérrez, M. Larrañaga-Cores, et al.
Archivos de la Sociedad Española de Oftalmología (English Edition) (2023) Vol. 99, Iss. 3, pp. 109-132
Closed Access | Times Cited: 2
RMD commentary, JAK kinase inhibitors: a preferred alternative to TNF inhibitors?
Vibeke Strand
RMD Open (2021) Vol. 7, Iss. 1, pp. e001565-e001565
Open Access | Times Cited: 4
Safety of upadacitinib in Latin American patients with rheumatoid arthritis: an integrated safety analysis of the SELECT phase 3 clinical program
Adriana María Kakehasi, Sebastião Cézar Radominski, Marcos Baravalle, et al.
Clinical Rheumatology (2023) Vol. 42, Iss. 5, pp. 1249-1258
Open Access | Times Cited: 1
Opportunistische Infektionen im Zusammenhang mit der Behandlung von rheumatoider Arthritis mit Januskinase-Inhibitoren: eine strukturierte Literaturübersicht
Kevin Winthrop, John D. Isaacs, Leonard H. Calabrese, et al.
Kompass Autoimmun (2023) Vol. 5, Iss. 3, pp. 104-113
Open Access | Times Cited: 1
Efectos secundarios oculares de las terapias oncológicas. Revisión
M. Asencio Durán, Eva Fernández-Gutiérrez, M. Larrañaga-Cores, et al.
Archivos de la Sociedad Española de Oftalmología (2023) Vol. 99, Iss. 3, pp. 109-132
Closed Access | Times Cited: 1
Herpes Zoster in Palate: Atypical Presentation in Immunosuppressed Patient Secondary to Rituximab, a Case Report and Review of Clinical Manifestations and Management
Trelles-Hernández Daniela, Camarillo-Noriega Carlos Alberto, Cruz-Villalobos Ricardo Alberto
International Journal of Medical Science and Clinical Research Studies (2024) Vol. 04, Iss. 01
Open Access
Janus Kinase Inhibitors as a Third-Line Therapy for Refractory Endogenous Noninfectious Uveitis
Justus G. Garweg, Kim A. Straessle
Ocular Immunology and Inflammation (2024), pp. 1-8
Closed Access
Real-world risk factors for herpes zoster in patients with rheumatoid arthritis undergoing tofacitinib treatment
Yi-Syuan Sun, De-Feng Huang, Wei‐Sheng Chen, et al.
Journal of the Chinese Medical Association (2024) Vol. 87, Iss. 11, pp. 988-992
Open Access
Herpes Zoster and Venous Thromboembolism Following Upadacitinib Treatment for Severe Atopic Dermatitis
Kawaiola Cael Aoki, Colin Burnette, S. Bartoš
Cureus (2024)
Open Access

Scroll to top